Title:
ANTI-STAT3 BISPECIFIC ANTIBODY HAVING CELL-PENETRATING ABILITY, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Document Type and Number:
WIPO Patent Application WO/2019/125033
Kind Code:
A1
Abstract:
The present invention relates to an anti-STAT3 bispecific antibody having a cell-penetrating ability, and a pharmaceutical composition containing same and, more specifically, to an anti-STAT3 bispecific antibody comprising a site specifically binding to STAT3 and a DNA binding site enabling cell-penetration, and a pharmaceutical composition containing same as an active ingredient. It has been ascertained that a STAT3/DNA bispecific antibody according to the present invention comprises a DNA binding site, which allows penetration into cells and specifically binds to intranuclear DNA, so as to be capable of overcoming limitations of a conventional antibody drug, which only targets proteins existing outside the cells, and binds specifically only to STAT3 in the active phosphorylated form so as to be capable of inhibiting the transcription factor activity thereof, thereby being effectively usable in the development of: therapeutic agents, having no side effects, for associated diseases caused by the activation of STAT3, for example, therapeutic agents for various carcinomas associated with the activation of STAT3; drugs capable of inhibiting cancer metastasis induced by the activation of STAT3; and therapeutic agents, having no side effects, for inflammatory diseases caused by the activation of STAT3, including rheumatoid arthritis.
Inventors:
HAHM SUNG HO (KR)
HONG JIN TAE (KR)
HONG JIN TAE (KR)
Application Number:
PCT/KR2018/016432
Publication Date:
June 27, 2019
Filing Date:
December 21, 2018
Export Citation:
Assignee:
ROPHIBIO INC (KR)
International Classes:
A61K39/395; A61K39/00; A61P19/02; A61P29/00; C07K16/18; C07K16/44; G01N33/68
Foreign References:
| US20170306048A1 | 2017-10-26 | |||
| KR20160050051A | 2016-05-10 | |||
| KR20090092201A | 2009-08-31 | |||
| US20160115248A1 | 2016-04-28 |
Other References:
GOICOCHEA, N. L. ET AL.: "Development of Cell -penetrating Bispecific Antibodies Targeting the N-terminal Domain of Androgen Receptor for Prostate Cancer Therapy", PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 30, no. 12, 1 December 2017 (2017-12-01), pages 785 - 793, XP055714950
MANNING G ET AL.: "the protein kinase complement of the human genome", SCIENCE, vol. 298, 2002, pages 1912 - 1934, XP002422776, DOI: 10.1126/science.1075762
RHEUMATOLOGY (OXFORD)., vol. 54, no. 6, June 2015 (2015-06-01), pages 1103 - 13
J AUTOIMMUN., vol. 11, no. 5, October 1998 (1998-10-01), pages 539 - 46
See also references of EP 3730150A4
MANNING G ET AL.: "the protein kinase complement of the human genome", SCIENCE, vol. 298, 2002, pages 1912 - 1934, XP002422776, DOI: 10.1126/science.1075762
RHEUMATOLOGY (OXFORD)., vol. 54, no. 6, June 2015 (2015-06-01), pages 1103 - 13
J AUTOIMMUN., vol. 11, no. 5, October 1998 (1998-10-01), pages 539 - 46
See also references of EP 3730150A4
Attorney, Agent or Firm:
KWAK, Jai Gun (KR)
Download PDF: